PARP inhibition prevents postinfarction myocardial remodeling and heart failure via the protein kinase C/glycogen synthase kinase-3β pathway

Anita Palfi, A. Tóth, Katalin Hanto, Peter Deres, Eszter Szabados, Zoltan Szereday, Gyozo Kulcsar, T. Kalai, K. Hideg, F. Gallyas, B. Sümegi, K. Tóth, R. Halmosi

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

The inhibition of glycogen synthase kinase-3β (GSK-3β) via phosphorylation by Akt or protein kinase C (PKC), or the activation of mitogen-activated protein kinase (MAPK) cascades can play a pivotal role in left ventricular remodeling following myocardial infarction. Our previous data showed that MAPK and phosphatidylinositol-3-kinase/Akt pathways could be modulated by poly(ADP-ribose)polymerase (PARP) inhibition raising the possibility that cardiac hypertrophic signaling responses may be favorably influenced by PARP inhibitors. A novel PARP inhibitor (L-2286) was tested in a rat model of chronic heart failure following isoproterenol-induced myocardial infarction. Subsequently, cardiac hypertrophy and interstitial collagen deposition were assessed; additionally, mitochondrial enzyme activity and the phosphorylation state of GSK-3β, Akt, PKC and MAPK cascades were monitored. PARP inhibitor (L-2286) treatment significantly reduced the progression of postinfarction heart failure attenuating cardiac hypertrophy and interstitial fibrosis, and preserving the integrity of respiratory complexes. More importantly, L-2286 repressed the hypertrophy-associated increased phosphorylation of panPKC, PKC α/βII, PKC δ and PKC ε, which could be responsible for the activation of the antihypertrophic GSK-3β. This work provides the first evidence that PARP inhibition beneficially modulates the PKC/GSK-3β intracellular signaling pathway in a rat model of chronic heart failure identifying a novel drug target to treat heart failure.

Original languageEnglish
Pages (from-to)149-159
Number of pages11
JournalJournal of Molecular and Cellular Cardiology
Volume41
Issue number1
DOIs
Publication statusPublished - Jul 2006

Fingerprint

Glycogen Synthase Kinase 3
2-((2-piperidin-1-ylethyl)thio)quinazolin-4(3H)-one
Poly(ADP-ribose) Polymerases
Protein Kinase C
Heart Failure
Mitogen-Activated Protein Kinases
Phosphorylation
Cardiomegaly
Myocardial Infarction
Phosphatidylinositol 3-Kinase
Ventricular Remodeling
Isoproterenol
Hypertrophy
Fibrosis
Collagen
Enzymes
Pharmaceutical Preparations
Poly(ADP-ribose) Polymerase Inhibitors

Keywords

  • Glycogen synthase kinase-3β
  • Heart failure
  • Intracellular signaling
  • PARP inhibition
  • Protein kinase C
  • Ventricular remodeling

ASJC Scopus subject areas

  • Molecular Biology
  • Cardiology and Cardiovascular Medicine

Cite this

PARP inhibition prevents postinfarction myocardial remodeling and heart failure via the protein kinase C/glycogen synthase kinase-3β pathway. / Palfi, Anita; Tóth, A.; Hanto, Katalin; Deres, Peter; Szabados, Eszter; Szereday, Zoltan; Kulcsar, Gyozo; Kalai, T.; Hideg, K.; Gallyas, F.; Sümegi, B.; Tóth, K.; Halmosi, R.

In: Journal of Molecular and Cellular Cardiology, Vol. 41, No. 1, 07.2006, p. 149-159.

Research output: Contribution to journalArticle

@article{424ccf12f8a0496b86637c79fadce21c,
title = "PARP inhibition prevents postinfarction myocardial remodeling and heart failure via the protein kinase C/glycogen synthase kinase-3β pathway",
abstract = "The inhibition of glycogen synthase kinase-3β (GSK-3β) via phosphorylation by Akt or protein kinase C (PKC), or the activation of mitogen-activated protein kinase (MAPK) cascades can play a pivotal role in left ventricular remodeling following myocardial infarction. Our previous data showed that MAPK and phosphatidylinositol-3-kinase/Akt pathways could be modulated by poly(ADP-ribose)polymerase (PARP) inhibition raising the possibility that cardiac hypertrophic signaling responses may be favorably influenced by PARP inhibitors. A novel PARP inhibitor (L-2286) was tested in a rat model of chronic heart failure following isoproterenol-induced myocardial infarction. Subsequently, cardiac hypertrophy and interstitial collagen deposition were assessed; additionally, mitochondrial enzyme activity and the phosphorylation state of GSK-3β, Akt, PKC and MAPK cascades were monitored. PARP inhibitor (L-2286) treatment significantly reduced the progression of postinfarction heart failure attenuating cardiac hypertrophy and interstitial fibrosis, and preserving the integrity of respiratory complexes. More importantly, L-2286 repressed the hypertrophy-associated increased phosphorylation of panPKC, PKC α/βII, PKC δ and PKC ε, which could be responsible for the activation of the antihypertrophic GSK-3β. This work provides the first evidence that PARP inhibition beneficially modulates the PKC/GSK-3β intracellular signaling pathway in a rat model of chronic heart failure identifying a novel drug target to treat heart failure.",
keywords = "Glycogen synthase kinase-3β, Heart failure, Intracellular signaling, PARP inhibition, Protein kinase C, Ventricular remodeling",
author = "Anita Palfi and A. T{\'o}th and Katalin Hanto and Peter Deres and Eszter Szabados and Zoltan Szereday and Gyozo Kulcsar and T. Kalai and K. Hideg and F. Gallyas and B. S{\"u}megi and K. T{\'o}th and R. Halmosi",
year = "2006",
month = "7",
doi = "10.1016/j.yjmcc.2006.03.427",
language = "English",
volume = "41",
pages = "149--159",
journal = "Journal of Molecular and Cellular Cardiology",
issn = "0022-2828",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - PARP inhibition prevents postinfarction myocardial remodeling and heart failure via the protein kinase C/glycogen synthase kinase-3β pathway

AU - Palfi, Anita

AU - Tóth, A.

AU - Hanto, Katalin

AU - Deres, Peter

AU - Szabados, Eszter

AU - Szereday, Zoltan

AU - Kulcsar, Gyozo

AU - Kalai, T.

AU - Hideg, K.

AU - Gallyas, F.

AU - Sümegi, B.

AU - Tóth, K.

AU - Halmosi, R.

PY - 2006/7

Y1 - 2006/7

N2 - The inhibition of glycogen synthase kinase-3β (GSK-3β) via phosphorylation by Akt or protein kinase C (PKC), or the activation of mitogen-activated protein kinase (MAPK) cascades can play a pivotal role in left ventricular remodeling following myocardial infarction. Our previous data showed that MAPK and phosphatidylinositol-3-kinase/Akt pathways could be modulated by poly(ADP-ribose)polymerase (PARP) inhibition raising the possibility that cardiac hypertrophic signaling responses may be favorably influenced by PARP inhibitors. A novel PARP inhibitor (L-2286) was tested in a rat model of chronic heart failure following isoproterenol-induced myocardial infarction. Subsequently, cardiac hypertrophy and interstitial collagen deposition were assessed; additionally, mitochondrial enzyme activity and the phosphorylation state of GSK-3β, Akt, PKC and MAPK cascades were monitored. PARP inhibitor (L-2286) treatment significantly reduced the progression of postinfarction heart failure attenuating cardiac hypertrophy and interstitial fibrosis, and preserving the integrity of respiratory complexes. More importantly, L-2286 repressed the hypertrophy-associated increased phosphorylation of panPKC, PKC α/βII, PKC δ and PKC ε, which could be responsible for the activation of the antihypertrophic GSK-3β. This work provides the first evidence that PARP inhibition beneficially modulates the PKC/GSK-3β intracellular signaling pathway in a rat model of chronic heart failure identifying a novel drug target to treat heart failure.

AB - The inhibition of glycogen synthase kinase-3β (GSK-3β) via phosphorylation by Akt or protein kinase C (PKC), or the activation of mitogen-activated protein kinase (MAPK) cascades can play a pivotal role in left ventricular remodeling following myocardial infarction. Our previous data showed that MAPK and phosphatidylinositol-3-kinase/Akt pathways could be modulated by poly(ADP-ribose)polymerase (PARP) inhibition raising the possibility that cardiac hypertrophic signaling responses may be favorably influenced by PARP inhibitors. A novel PARP inhibitor (L-2286) was tested in a rat model of chronic heart failure following isoproterenol-induced myocardial infarction. Subsequently, cardiac hypertrophy and interstitial collagen deposition were assessed; additionally, mitochondrial enzyme activity and the phosphorylation state of GSK-3β, Akt, PKC and MAPK cascades were monitored. PARP inhibitor (L-2286) treatment significantly reduced the progression of postinfarction heart failure attenuating cardiac hypertrophy and interstitial fibrosis, and preserving the integrity of respiratory complexes. More importantly, L-2286 repressed the hypertrophy-associated increased phosphorylation of panPKC, PKC α/βII, PKC δ and PKC ε, which could be responsible for the activation of the antihypertrophic GSK-3β. This work provides the first evidence that PARP inhibition beneficially modulates the PKC/GSK-3β intracellular signaling pathway in a rat model of chronic heart failure identifying a novel drug target to treat heart failure.

KW - Glycogen synthase kinase-3β

KW - Heart failure

KW - Intracellular signaling

KW - PARP inhibition

KW - Protein kinase C

KW - Ventricular remodeling

UR - http://www.scopus.com/inward/record.url?scp=33745391346&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745391346&partnerID=8YFLogxK

U2 - 10.1016/j.yjmcc.2006.03.427

DO - 10.1016/j.yjmcc.2006.03.427

M3 - Article

C2 - 16716347

AN - SCOPUS:33745391346

VL - 41

SP - 149

EP - 159

JO - Journal of Molecular and Cellular Cardiology

JF - Journal of Molecular and Cellular Cardiology

SN - 0022-2828

IS - 1

ER -